Uses of targeted oxidative therapeutic formulation in arteriosclerosis
OwnerRobert F. Hofmann, Robert H. Carpenterinventors
Life of this patent
Estimating the term…
Abstract
The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.
Claims55
An article of manufacture comprising:
- a first container containing a liquid phase, the liquid phase comprising:
- peroxidic species or reaction products resulting from oxidation of a alkene by a mixture of ozone and oxygen, wherein the alkene has less than about 35 carbons;
- a penetrating solvent;
- and
- a second container containing a solid phase, the solid phase comprising:
- a dye containing a chelated divalent or trivalent metal;
- and
- an aromatic redox compound.
An article of manufacture comprising:
- a first container containing a liquid phase, the liquid phase comprising:
- peroxidic species or reaction products resulting from oxidation of a hydroxyl-containing alkene by a mixture of ozone and oxygen, wherein the hydroxyl-containing comprises α-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, menthol, geranylgeraniol or famesol alkene by a mixture of ozone and oxygen;
- and
- a penetrating solvent, wherein the penetrating solvent comprises dimethylsulfoxide, sterol, lecithin, propylene glycol, or methylsulfonylmethane;
- and
- a second container containing a solid phase, the solid phase comprising:
- a dye containing a chelated divalent or trivalent metal, wherein the dye comprises porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein;
- and
- an aromatic redox compound, wherein the redox compound comprises benzoquinone or naphthoquinone.
A method for treating a patient with coronary arteriosclerosis comprising:
- administering to the patient an effective amount of a pharmaceutical formulation comprising:
- peroxidic species or reaction products resulting from oxidation of an alkene by an oxygen-containing oxidizing agent, wherein the alkene has less than about 35 carbons;
- a penetrating solvent;
- a dye containing a chelated divalent or trivalent metal;
- and
- an aromatic redox compound.
A method for treating a patient with coronary arteriosclerosis comprising:
- administering to the patient an effective amount of a pharmaceutical formulation comprising:
- peroxidic species or reaction products resulting from oxidation of a hydroxyl-containing alkene by a mixture of ozone and oxygen, wherein the hydroxyl-containing comprises α-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, menthol, geranylgeraniol or famesolalkene by a mixture of ozone and oxygen;
- a penetrating solvent, wherein the penetrating solvent comprises dimethylsulfoxide, sterol, lecithin, propylene glycol, or methylsulfonylmethane;
- a dye containing a chelated divalent or trivalent metal, wherein the dye comprises porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein;
- and
- an aromatic redox compound, wherein the redox compound comprises benzoquinone or naphthoquinone.
Dependencies are inferred from the claim text.